- Conditions
- Parkinson Disease
- Interventions
- LY3884961, Methylprednisolone, Sirolimus
- Biological · Drug
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Murrieta, California • Englewood, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Frontotemporal Dementia
- Interventions
- LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone
- Biological · Drug
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 4
- States / cities
- Maitland, Florida • Orlando, Florida • Burlington, Massachusetts + 1 more
- Conditions
- Parkinson's Disease
- Interventions
- LY3962681, Placebo (aCSF)
- Drug · Other
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- Englewood, Colorado • New Haven, Connecticut • Naples, Florida + 4 more
- Conditions
- Gaucher Disease, Gaucher Disease, Type 1
- Interventions
- LY3884961
- Genetic
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Fairfax, Virginia
- Conditions
- Gaucher Disease, Type 2
- Interventions
- LY3884961, Methylprednisolone, Sirolimus, Prednisone
- Genetic · Drug
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 0 Months to 24 Months
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Oakland, California • Minneapolis, Minnesota • New York, New York + 2 more